Preview

Rational Pharmacotherapy in Cardiology

Advanced search

THE PROBLEM OF THE USE OF NEW ORAL ANTICOAGULANTS IN CANCER PATIENTS RECEIVING CHEMOTHERAPY

https://doi.org/10.20996/1819-6446-2014-10-6-634-639

Full Text:

Abstract

Despite large number of known risk factors of venous thromboembolism (VTE) in cancer patients existing prediction models do not allow definite identification of cancer patients that have indications for anticoagulant prevention. Besides, heparin and warfarin use for VTE prevention in cancer is accompanied by some problems. New oral anticoagulants (NOAC) are promising drugs for use in oncology practice; however their use is complicated by the lack of data on efficacy and safety in these patients, potential drug interactions and the possibility of unpredictable changes in effect during chemotherapy. Widespread use of NOAC for the prevention and treatment of tumor-associated VTE prior to phase III trials is not recommended. However, the criteria for selection of patients for whom the study of the efficacy and safety of NOAC is a priority can now be developed.

About the Authors

A. A. Rumyantsev
Russian Cancer Research Center named after N.N. Blokhin
Russian Federation
Kashirskoye shosse 23, Moscow, 115478 Russia


I. A. Pokataev
Russian Cancer Research Center named after N.N. Blokhin
Russian Federation
Kashirskoye shosse 23, Moscow, 115478 Russia


T. V. Kozlov
I.M. Sechenov First Moscow State Medical University
Russian Federation
Trubetskaya ul. 8-2, Moscow, 119991 Russia


N. A. Rumyantsev
I.M. Sechenov First Moscow State Medical University
Russian Federation
Trubetskaya ul. 8-2, Moscow, 119991 Russia


References

1. NCCN Clinical Practice Guidelines in Oncology. Cancer-associated Venous Thromboembolic disease. Version

2. 2014. Available at: http://www.nccn.org/professionals/physician_gls/pdf/vte.pdf. Accessed by 06.12.2014

3. Khorana AA, Kuderer N, Culakova E, et al. Development and validation of a predictive model for chemotherapyassociated thrombosis. Blood 2008;111: 4902-7.

4. Gary T, Belaj K, Steidl K, et al. Asymptomatic deep vein thrombosis and superficial vein thrombosis in ambulatory cancer patients: impact on short-term survival. Br J Cancer 2012;107:1244-8.

5. Palumbo JS, Talmage KE, Massari JV et al. Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent and-independent mechanisms. Blood 2007;110:133-141.

6. Monreal M, Falga C, Valdes M et al. Fatal pulmonary embolism and fatal bleeding in cancer patients with venous thromboembolism: findings from the RIETE registry. J Thromb Haemost 2006;4: 1950-6.

7. Khorana AA, Connolly GC. Assessing Risk of Venous Thromboembolism in the Patient With Cancer. J Clin Oncol 2009;27:4839-47.

8. Konigsbrugge O, Pabinger I, Ay C. Risk factors for venous thromboembolism in cancer: novel findings from the Vienna Cancer and Thrombosis Study (CATS). Thrombosis Research 2014;133:39-43.

9. Roach REJ, Lijfering WM, van Hylckama VA et al. The risk of venous thrombosis in individuals with a history of superficial vein thrombosis and acquired venous thrombotic risk factors. Blood 2013;122: 4264-9.

10. Riedl J, Kaider A, Reitter E-M et al. Association of mean platelet volume with risk of venous thromboembolism and mortality in patients with cancer: results from the Vienna Cancer and Thrombosis Study (CATS). Thromb Haemost 2013;111:670-8.

11. Thaler J, Ay C, Pabinger I. Venous thromboembolism in cancer patients - risk scores and recent randomized controlled trials. Thromb Haemost 2012;108:1042-8.

12. Short N, Connors J. New Oral Anticoagulants and the Cancer Patient. The Oncologist 2014; 19: 82-93.

13. Spinler SA. New Concepts in Heparin-Induced Thrombocytopenia: Diagnosis and Management. J Thromb Thrombolysis 2006;21(1):17-21.

14. Levine MN, Gu C, Liebman HA, et al. A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer. J Thromb Haemost 2012;10(5):807-14

15. Apixaban for the Prevention of Venous Thromboembolism in Cancer Patients (AVERT). Available at: http://clinicaltrials.gov/ct2/show/NCT02048865. Accessed by 06.12.2014

16. Gerotziafas GT, Mahe I, Elalamy I. New orally active anticoagulants agents for the prevention and treatment of venous thromboembolism in cancer patients. Ther Clin Risk Manag 2014;10: 423-36.


For citation:


Rumyantsev A.A., Pokataev I.A., Kozlov T.V., Rumyantsev N.A. THE PROBLEM OF THE USE OF NEW ORAL ANTICOAGULANTS IN CANCER PATIENTS RECEIVING CHEMOTHERAPY. Rational Pharmacotherapy in Cardiology. 2014;10(6):634-639. (In Russ.) https://doi.org/10.20996/1819-6446-2014-10-6-634-639

Views: 400


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)